Shire acquires NPS Pharma for $5.2 billion including Gattex/Revestive and Natpara

Shire plc and NPS Pharmaceuticals, Inc. announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 billion. Shire will accelerate the growth of NPS Pharma’s innovative portfolio through its market expertise in gastrointestinal (GI) disorders, core capabilities in rare disease patient management, and global footprint. The transaction has been approved unanimously by the Boards of Directors of both Shire and NPS Pharma. NPS Pharma is a rare disease-focused biopharmaceutical company and its first product, Gattex/Revestive (teduglutide [rDNA origin]) for injection, is approved in the United States and Europe to treat adults with Short Bowel Syndrome (SBS) who are dependent on parenteral support. NPS Pharma also has a registration phase product, Natpara/Natpar (rhPTH -83) for the treatment of Hypoparathyroidism (HPT). In Europe, Revestive is indicated for the treatment of adult patients with Short Bowel Syndrome who should be stable following a period of intestinal adaptation after surgery.